Search Results - "KANNOURAKIS, G"

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial by Escudier, B, Michaelson, M D, Motzer, R J, Hutson, T E, Clark, J I, Lim, H Y, Porfiri, E, Zalewski, P, Kannourakis, G, Staehler, M, Tarazi, J, Rosbrook, B, Cisar, L, Hariharan, S, Kim, S, Rini, B I

“…Background: In the AXIS trial, axitinib prolonged progression-free survival (PFS) vs sorafenib in patients with advanced renal cell carcinoma (RCC) previously…”
Get full text

EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma by Davis, I.D., Long, A., Yip, S., Espinoza, D., Thompson, J.F., Kichenadasse, G., Harrison, M., Lowenthal, R.M., Pavlakis, N., Azad, A., Kannourakis, G., Steer, C., Goldstein, D., Shapiro, J., Harvie, R., Jovanovic, L., Hudson, A.L., Nelson, C.C., Stockler, M.R., Martin, A.

“…We hypothesised that alternating inhibitors of the vascular endothelial growth factor receptor (VEGFR) and mammalian target of rapamycin pathways would delay…”
Get full text

Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia by Dale, David C., Person, Richard E., Bolyard, Audrey Anna, Aprikyan, Andrew G., Bos, Cindy, Bonilla, Mary Ann, Boxer, Laurence A., Kannourakis, George, Zeidler, Cornelia, Welte, Karl, Benson, Kathleen F., Horwitz, Marshall

“…Congenital neutropenia and cyclic neutropenia are disorders of neutrophil production predisposing patients to recurrent bacterial infections. Recently the…”
Get full text

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial by Zdenkowski, N., Forbes, J.F., Boyle, F.M., Kannourakis, G., Gill, P.G., Bayliss, E., Saunders, C., Della-Fiorentina, S., Kling, N., Campbell, I., Mann, G.B., Coates, A.S., Gebski, V., Davies, L., Thornton, R., Reaby, L., Cuzick, J., Green, M.

“…Despite the effectiveness of adjuvant endocrine therapy in preventing breast cancer recurrence, breast cancer events continue at a high rate for at least 10…”
Get full text

P776: A PHASE 2, OPEN‐LABEL, ASCENDING DOSE STUDY OF KER‐050 FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES by Tan, S., Arbelaez, A., Chee, L., Fong, C. Y., Hiwase, D., Kannourakis, G., Kwan, J., Liang, J., Puliyayil, A., Rose, H., Ross, D., Teh, T.‐C., Westerman, D., Wight, J., Feng, W., Lachey, J., McGinty, A., Natarajan, H., Rovaldi, C., Cooper, S.

Get full text

P0211 EVERSUN: A phase 2 trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (ANZUP Trial 0901) by Davis, I.D, Long, A, Martin, A, Espinoza, D, Yip, S, Thompson, J.F, Kichenadasse, G, Harrison, M, Lowenthal, R.M, Pavlakis, N, Azad, A, Kannourakis, G, Steer, C, Goldstein, D, Shapiro, J, Stockler, M.R

“…Background We hypothesised that alternating treatment with inhibitors of the VEGFR and mTOR pathways would delay the development of resistance in advanced…”
Get full text

Neoadjuvant chemotherapy with sequential anthracycline–docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem) by McCarthy, N, Boyle, F, Zdenkowski, N, Bull, J, Leong, E, Simpson, A, Kannourakis, G, Francis, P.A, Chirgwin, J, Abdi, E, Gebski, V, Veillard, A.S, Zannino, D, Wilcken, N, Reaby, L, Lindsay, D.F, Badger, H.D, Forbes, J.F

“…Abstract Background Neoadjuvant chemotherapy has a sound rationale for use in women with large operable breast cancer, and achievement of pathological complete…”
Get full text

The role of cytokines in the pathogenesis of Langerhans cell histiocytosis by Kannourakis, G, Abbas, A

“…Langerhans cell histiocytosis (LCH) is characterised by an accumulation of cells ('LCH cells') with the same phenotypic features as normal Langerhans cells…”
Get full text

bcl-2 Transgene Expression can Protect Neurons Against Developmental and Induced Cell Death by Farlie, Peter G., Dringen, Ralf, Rees, Sandra M., Kannourakis, George, Bernard, Ora

“…The bcl-2 protooncogene, which protects various cell types from apoptotic cell death, is expressed in the developing and adult nervous system. To explore its…”
Get full text

Effects of Recombinant Human Granulocyte Colony-Stimulating Factor on Hematopoietic Progenitor Cells in Cancer Patients by Dührsen, Ulrich, Villeval, Jean-Luc, Boyd, Janis, Kannourakis, George, Morstyn, George, Metcalf, Donald

“…Hematopoietic progenitor cell levels were monitored in the peripheral blood and bone marrow of 30 cancer patients receiving recombinant human…”
Get full text

Three Cases of Activation of Cutaneous Squamous-cell Carcinoma During Treatment with Prolonged Administration of Rituximab by Fogarty, G.B., Bayne, M., Bedford, P., Bond, R., Kannourakis, G.

Get full text

Perivascular T Cells Express the Pro‐Inflammatory Chemokine RANTES mRNA in Multiple Sclerosis Lesions by HVAS, J., McLEAN, C., JUSTESEN, J., KANNOURAKIS, G., STEINMAN, L., OKSENBERG, J. R., BERNARD, C. C. A.

“…Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS), characterized by accumulation of mononuclear cells. The…”
Get full text

Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib by Sharma, R., Kadife, E., Kannourakis, G., Ahmed, N., Prithviraj, P.

Get full text

The biology of erythropoietin and its role in the anaemia of prematurity by Kannourakis, G

Get more information

Foxp3+ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity by Mitchell, Jenée, Kelly, Jason, Kvedaraite, Egle, von Bahr Greenwood, Tatiana, Henter, Jan-Inge, Pellicci, Daniel G., Berzins, Stuart P., Kannourakis, George

“…Langerhans cell histiocytosis (LCH) lesions contain myeloid lineage ‘LCH’ cells. Regulatory T cells (Tregs) are also enriched within lesions, although their…”
Get full text

A time to kill: viral manipulation of the cell death program by Hay, Stewart, Kannourakis, George

“…The Fiona Elsey Cancer Research Laboratory, Cancer Research Centre, School of Science, University of Ballarat, St John of God Hospital, 1002 Mair Street,…”
Get full text

Co-Expression of CD56 and Production of Transforming Growth Factor Beta By Foxp3 Regulatory T Cells from Langerhans Cell Histiocytosis Lesions by Mitchell, Jenee, Kvedaraite, Egle, von Bahr Greenwood, Tatiana, Henter, Jan-Inge, Pellicci, Daniel G, Berzins, Stuart P, Kannourakis, George

“…Introduction: Langerhans cell histiocytosis (LCH) is a rare disease involving inflammatory lesions that can occur in essentially any organ of the body. LCH…”
Get full text

Altered Populations of Unconventional T Cell Lineages in Patients with Langerhans Cell Histiocytosis by Mitchell, Jenée, Kvedaraite, Egle, von Bahr Greenwood, Tatiana, Henter, Jan-Inge, Pellicci, Daniel G., Berzins, Stuart P., Kannourakis, George

“…Langerhans cell histiocytosis (LCH) lesions are defined by the presence of CD1a + /CD207 + myeloid cells, but many other immune cells are present including…”
Get full text

Pharmacokinetics of Human Granulocyte-Macrophage Colony-Stimulating Factor Using A Sensitive Immunoassay by Cebon, Jonathan, Dempsey, Peter, Fox, Richard, Kannourakis, George, Bonnem, Eric, Burgess, Antony W., Morstyn, George

“…A sensitive and reliable sandwich enzyme-linked immunosorbent assay (ELISA) has been developed for recombinant human granulocyte-macrophage colony-stimulating…”
Get full text

Plasma Signalling Factors in patients with Langerhans Cell Histiocytosis (Lch) Correlate with Relative Frequencies of Lch cells and T cells within Lesions by Mitchell, J, Kvedaraite, E, Greenwood, TV, Lourda, M, Henter, JI, Berzins, S, Kannourakis, G

Get full text